<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1907233882
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2006
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        VANCOLON 1GM POWDER FOR I.V. INFUSION
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        VANCOMYCIN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        g
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Parenteral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Powder for solution for injection/infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        Store below 30°C ,  protect from Light
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        58.6
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Gulf Pharmaceutical Industries (Julphar)" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Gulf Pharmaceutical Industries (Julphar)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Gulf Pharmaceutical Industries (Julphar)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J01XA01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        A07AA09
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Vancolon</strong> is an antibiotic that belongs to a group of antibiotics called &ldquo;glycopeptides&rdquo;. <strong>Vancolon</strong> works by eliminating certain bacteria that cause infections.</p><p><strong>Vancolon</strong> powder is made into a solution for infusion.</p><p><strong>Vancolon</strong> is used in all age groups by infusion for the treatment of the following serious infections:&nbsp;</p><p>&bull;&nbsp; Infections of the skin and tissues below the skin.</p><p>&bull;&nbsp; Infections of bone and joints.</p><p>&bull;&nbsp; An infection of the lungs called &ldquo;pneumonia&rdquo;.</p><p>&bull;&nbsp; Infection of the inside lining of the heart (endocarditis) and to prevent endocarditis in patients at risk when undergoing major surgical procedures.</p><p>&bull;&nbsp; Infection in central nervous system,</p><p>&bull;&nbsp; Infection in the blood linked to the infections listed above.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use Vancolon</strong></p><p>&bull;&nbsp; If you are allergic to vancomycin hydrochloride.</p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor, hospital pharmacist or nurse before using <strong>Vancolon</strong> if:</p><p>&bull;&nbsp; You suffered a previous allergic reaction to teicoplanin because this could mean you are also allergic to vancomycin.</p><p>&bull;&nbsp; You have a hearing disorder; especially if you are elderly (you may need hearing tests during treatment).</p><p>&bull;&nbsp; You have kidney disorder (you will need to have your blood and kidneys tested during treatment).</p><p>&bull;&nbsp; You are receiving vancomycin by infusion for the treatment of the diarrhoea associated to Clostridium difficile infection instead of orally.</p><p><strong>Talk to your doctor, hospital pharmacist or nurse during treatment with Vancolon if:</strong></p><p>&bull;&nbsp; You are receiving Vancolon for a long time (you may need to have your blood, liver and kidneys tested during treatment).</p><p>&bull;&nbsp; You develop any skin reaction during the treatment.</p><p>&bull;&nbsp; You develop severe or prolonged diarrhoea during or after using vancomycin, consult your doctor immediately. This may be a sign of bowel inflammation (pseudomembranous colitis) which can occur following treatment with antibiotics.</p><p><strong>Children</strong></p><p><strong>Vancolon </strong>will be used with particular care in premature infants and young infants, because their kidneys are not fully developed and they may accumulate vancomycin in the blood. This age group may need blood tests for controlling vancomycin levels in blood.</p><p>Concomitant administration of vancomycin and anaesthetic agents has been associated with skin redness (erythema) and allergic reactions in children. Similarly, concomitant use with other medicines such as aminoglycoside antibiotics or nonsteroidal antiinflammatory agents (NSAIDs, e.g., ibuprofen) or amphotericin B (medicine for fungal infection) can increase the risk of kidney damage and therefore more frequent blood and renal test may be necessary.</p><p><strong>Other medicines and Vancolon</strong></p><p>Tell your doctor, pharmacist or nurse if you are taking, have recently taken, or might take any other medicines. Moreover, do not take any new medicine without consulting your doctor.</p><p><strong>The following medicines may react with vancomycin if you take them at the same time, such as medicines for the treatment of:</strong></p><p>&bull;&nbsp; infections caused by bacteria (streptomycin, neomycin, gentamicin, kanamycin, amikacin, bacitracin, tobramycin, polymixin B, colistin),</p><p>&bull;&nbsp; tuberculosis (viomycin),</p><p>&bull;&nbsp; fungal infections (amphotericin B),</p><p>&bull;&nbsp; cancer (cisplatin)</p><p>and</p><p>&bull;&nbsp; medicines for muscle relaxation during anaesthesia,</p><p>&bull;&nbsp; anaesthetic agents (if you are going to have general anaesthesia).</p><p>Your doctor may need to test your blood and adjust the dosage if vancomycin is given simultaneously with other medicines.</p><p><strong>Pregnancy</strong></p><p>If you are pregnant, think you may be pregnant or plan to become pregnant, tell your doctor before taking this medicine. Vancomycin should be given during pregnancy and breast-feeding only if clearly needed. Your doctor will decide if you should take Vancomycin.</p><p><strong>Breast-feeding</strong></p><p>Tell your doctor if you are breastfeeding, since Vancomycin passes into breast milk. Your doctor will decide whether vancomycin is really necessary or whether you should stop breastfeeding.</p><p><strong>Driving and using machines</strong></p><p>Vancomycin has no or negligible effect on the ability to drive and use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>You will be given <strong>Vancolon</strong> by medical staff while you are in hospital. Your doctor will decide how much of this medicine you should receive each day and how long the treatment will last.</p><p><strong>Dosage</strong></p><p>The dose given to you will depend on:</p><p>&bull;&nbsp; your age,</p><p>&bull;&nbsp; your weight,</p><p>&bull;&nbsp; the infection you have,</p><p>&bull;&nbsp; how well your kidneys are working,</p><p>&bull;&nbsp; your hearing ability,</p><p>&bull;&nbsp; any other medicines you may be taking.</p><p><strong><u>Adults and adolescents (from 12 years and older)</u></strong></p><p>The dosage will be calculated according to your body weight. The usual infusion dose is 15 to 20mg for each kg of body weight. It is usually given every 8 to 12 hours.</p><p>In some cases, your doctor may decide to give an initial dose of up to 30 mg for each kg of body weight. The maximum daily dose should not exceed 2 g.</p><p><strong><u>Use in children</u></strong></p><p><u>Children aged from one month to less than 12 years of age</u></p><p>The dosage will be calculated according to your body weight. The usual infusion dose is 10 to 15mg for each kg of body weight. It is usually given every 6 hours.</p><p><u>Preterm and term new-born infants (from 0 to 27 days)</u></p><p>The dosage will be calculated according to post-menstrual age (time elapsed between the first day of the last menstrual period and birth (gestational age) plus the time elapsed after birth (post-natal age).</p><p>The elderly, pregnant women and patients with a kidney disorder, including those on dialysis, may need a different dose.</p><p><strong>Method of administration</strong></p><p>Intravenous infusion means that the medicine flows from an infusion bottle or bag through a tube to one of your blood vessels and into your body. Your doctor, or nurse, will always give vancomycin into your blood and not in the muscle.</p><p>Vancomycin will be given into your vein for at least 60 minutes.</p><p><strong>Duration of treatment</strong></p><p>The length of treatment depends on the infection you have and may last a number of weeks.</p><p>The duration of the therapy may be different depending on the individual response to treatment for every patient.</p><p>During the treatment, you might have blood tests, be asked to provide urine samples and possibly have hearing tests to look for signs of possible side effects.</p><p><strong>If you receive more Vancolon than you should </strong></p><p>As <strong>Vancolon</strong> will be given to you whilst you are in hospital is unlikely that you will be given too much, however, tell your doctor or nurse immediately if you have any concerns.</p><p><strong>If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p><strong>Vancolon can cause allergic reactions, although serious allergic reactions (anaphylactic shock) are rare. Tell your doctor immediately if you get any sudden wheeziness, difficulty in breathing, redness on the upper part of the body, rash or itching.</strong></p><p>The absorption of vancomycin from the gastrointestinal tract is negligible.</p><p>However, if you have an inflammatory disorder of the digestive tract, especially if you also have a kidney disorder, side effects that occur when vancomycin is administered by infusion may appear.</p><p><strong>Common side effects (may affect up to 1 in 10 people):</strong></p><p>&bull;&nbsp; Fall in blood pressure</p><p>&bull;&nbsp; Breathlessness, noisy breathing (a high pitched sound resulting from obstructed air flow in the upper airway)</p><p>&bull;&nbsp; Rash and inflammation of the lining of the mouth, itching, itching rash, hives</p><p>&bull;&nbsp; Kidney problems which may be detected primarily by blood tests</p><p>&bull;&nbsp; Redness of upper body and face, inflammation of a vein</p><p><strong>Uncommon side effects (may affect up to 1 in 100 people):</strong></p><p>&bull;&nbsp; Temporary or permanent loss of hearing</p><p><strong>Rare side effects (may affect up to 1 in 1,000 people):</strong></p><p>&bull;&nbsp; Decrease in white blood cells, red blood cells and platelets (blood cells responsible for blood clotting)</p><p>&bull;&nbsp; Increase in some of the white cells in the blood</p><p>&bull;&nbsp; Loss of balance, ringing in your ears, dizziness</p><p>&bull;&nbsp; Blood vessel inflammation</p><p>&bull;&nbsp; Nausea (feeling sick)</p><p>&bull;&nbsp; Inflammation of the kidneys and kidney failure</p><p>&bull;&nbsp; Pain in the chest and back muscles</p><p>&bull;&nbsp; Fever, chills</p><p><strong>Very rare side effects (may affect up to 1 in 10,000 people):</strong></p><p>&bull;&nbsp; Sudden onset of severe allergic skin reaction with skin flaking blistering or peeling skin. This may be associated with a high fever and joint pains</p><p>&bull;&nbsp; Cardiac arrest</p><p>&bull;&nbsp; Inflammation of the bowel which causes abdominal pain and diarrhoea, which may contain blood</p><p><strong>Not known (frequency cannot be estimated from the available data):</strong></p><p>&bull;&nbsp; Being sick (throwing up), diarrhoea</p><p>&bull;&nbsp; Confusion, drowsiness, lack of energy, swelling, fluid retention, decreased urine</p><p>&bull;&nbsp; Rash with swelling or pain behind the ears, in the neck, groin, under the chin and armpits (swollen lymph nodes), abnormal blood and liver function tests</p><p>&bull;&nbsp; Rash with blisters and fever.</p><p><strong><u>To report any side effect(s):</u></strong></p><p>If you get any side effects, talk to your doctor, hospital pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via:</p><p>&bull;&nbsp; <strong>KSA: </strong></p><p><strong>The National Pharmacovigilance Centre (NPC):</strong></p><p><strong>-&nbsp; SFDA Call Centre: </strong>19999</p><p><strong>-&nbsp; E-mail: </strong>npc.drug@sfda.gov.sa</p><p><strong>-&nbsp; Website: </strong>https://ade.sfda.gov.sa</p><p>&bull;&nbsp; <strong>Other GCC States:</strong></p><p>- Please contact the relevant competent authority</p><p>By reporting side effects you can help provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep out of the reach and sight of children.</p><p>&ndash;&nbsp;&nbsp; Do not use <strong>Vancolon</strong> after the expiry date which is stated on the carton and vial. The expiry date refers to the last day of that month.</p><p>&ndash;&nbsp;&nbsp; Store below 30<sup>o</sup>C. Protect from light and heat. After reconstitution, store at room temperature for not more than 24 hours, or in a refrigerator (2-8&deg;C) for not more than 96 hours. for more information refer to section &ldquo;Special precautions for disposal and other handling &ldquo;</p><p>&ndash;&nbsp;&nbsp; Do not use <strong>Vancolon</strong> if you notice any visible sign of deterioration.</p><p>&ndash;&nbsp;&nbsp; Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is vancomycin. Each vial contains vancomycin hydrochloride equivalent to 0.5gm or 1gm vancomycin.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Vancolon 0.5gm sterile powder for IV infusion is available in packs containing one or 10 vials.
Vancolon 1gm sterile powder for IV infusion is available in packs containing one vial.
* Not all pack sizes may be marketed.


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Gulf Pharmaceutical Industries &quot;Julphar&quot;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                 30/12/2024
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL"><strong>فانكولون</strong> هو مضاد حيوي ينتمي إلى مجموعة من الأدوية تعرف باسم جلايكوببتايد. يعمل<strong> فانكولون </strong>عن طريق القضاء على أنواع معينة من البكتيريا المسببة في حدوث العدوى.</p><p dir="RTL"><strong>فانكولون </strong>عبارة عن مسحوق لتحضير محلول للتسريب الوريدي.</p><p dir="RTL">يتم استعمال <strong>فانكولون </strong>في جميع الفئات العمرية عن طريق التسريب الوريدي لعلاج حالات العدوى الخطيرة التالية:</p><p dir="RTL">&middot;&nbsp; عدوى الجلد والأنسجة تحت الجلد</p><p dir="RTL">&middot;&nbsp; عدوى العظام والمفاصل</p><p dir="RTL">&middot;&nbsp; عدوى الرئة (الالتهاب الرئوي)</p><p dir="RTL">&middot;&nbsp; عدوى بطانة القلب الداخلية (التهاب الشغاف) والوقاية من الإصابة بالتهاب الشغاف من قبل المرضى المعرضين لخطر حدوث ذلك أثناء الخضوع لعمليات جراحية كبرى</p><p dir="RTL">&middot;&nbsp; عدوى الجهاز العصبي المركزي</p><p dir="RTL">&middot;&nbsp; عدوى الدم المرتبط بحالات العدوى المذكورة أعلاه.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>يجب عدم استعمال فانكولون في الحالات التالية</strong><strong>:</strong></p><p dir="RTL">&middot;&nbsp; إذا كنت تعاني من الحساسية تجاه فانكومايسين هيدروكلوريد.</p><p dir="RTL"><strong>تحذيرات واحتياطات</strong></p><p dir="RTL">يرجى منك التحدث إلى طبيبك المعالج، الصيدلي في المستشفى أو الممرض قبل أن يتم إعطائك<strong> فانكولون </strong>في الحالات التالية:</p><p dir="RTL">&middot;&nbsp; إذا عانيت مسبقاً من تفاعل تحسسي تجاه تيكوبلانين، حيث أنك قد تعاني أيضاً من الحساسية تجاه فانكومايسين.</p><p dir="RTL">&middot;&nbsp; إذا كنت تعاني من اضطراب في حاسة السمع، وبصفة خاصة إذا كنت من فئة كبار السن (قد تكون بحاجة إلى إجراء فحص للسمع أثناء تلقي العلاج).</p><p dir="RTL">&middot;&nbsp; إذا كنت تعاني من اضطراب في الكلى (قد تكون بحاجة إلى فحص الدم والكلى لديك أثناء تلقي العلاج).</p><p dir="RTL">&middot;&nbsp; إذا كنت تتلقى فانكومايسين<strong> </strong>عن طريق التسريب الوريدي عوضاً عن طريق الفم لعلاج الإسهال المرتبط بالعدوى الناجمة عن بكتيريا كلوستريديوم ديفيسيل.</p><p dir="RTL"><strong>يرجى منك إخبار طبيبك المعالج، الصيدلي في المستشفى أو الممرض أثناء فترة تلقي العلاج باستخدام فانكولون في الحالات التالية:</strong></p><p dir="RTL">&middot;&nbsp; إذا كنت تتلقى فانكولون لفترة زمنية طويلة (قد تكون بحاجة إلى فحص الدم، الكبد والكلى أثناء فترة تلقي العلاج).</p><p dir="RTL">&middot;&nbsp; إذا عانيت من أية تفاعلات جلدية أثناء فترة تلقي العلاج.</p><p dir="RTL">&middot;&nbsp; إذا عانيت من الإسهال الشديد أو بصورة مستمرة أثناء أو بعد تلقي العلاج باستخدام فانكومايسين، في هذه الحالة يرجى منك استشارة طبيبك المعالج على الفور. قد يكون ذلك إحدى علامات حدوث التهاب في الأمعاء (التهاب&nbsp;القولون&nbsp;الغشائي الكاذب)، الذي من الممكن أن يحدث بعد تلقي العلاج باستخدام المضادات الحيوية.</p><p dir="RTL"><strong>الأطفال</strong></p><p dir="RTL">سوف يتم استعمال <strong>فانكولون </strong>بعناية خاصة لدى الأطفال الخدج والأطفال حديثي الولادة، نظراً لعدم نمو الكلى لديهم بشكل تام مما قد يؤدي إلى تراكم فانكومايسين في الدم. قد تحتاج هذه الفئة من المرضى لإجراء فحوصات الدم وذلك لمراقبة مستويات فانكومايسين في الدم.</p><p dir="RTL">ارتبط الاستخدام المتزامن للفانكومايسين مع أدوية التخدير بحدوث احمرار الجلد (حمامى) وتفاعلات حساسية لدى الأطفال. كما ارتبط استخدام فانكومايسين بالتزامن مع أدوية أخرى على سبيل المثال المضادات الحيوية من مجموعة الأمينوغلايكوسيدات، مضادات الالتهاب غير الستيرويدية (على سبيل المثال: إيبوبروفين) أو الأمفوتيريسين ب (دواء لعلاج حالات العدوى الفطرية) بحدوث زيادة في خطر الإصابة بتلف في الكلى و لذلك من الضروري الخضوع لفحوصات الدم والكلى بشكل دوري.</p><p dir="RTL"><strong>استعمال الأدوية الأخرى بالتزامن مع </strong>&nbsp;<strong>فانكولون</strong></p><p dir="RTL">يرجى منك إخبار طبيبك المعالج، الصيدلي الذي تتعامل معه أو الممرض، إذا كنت تتناول، تناولت مؤخراً أو قد تتناول أية أدوية أخرى. كما يرجى منك عدم تناول أي دواء جديد دون استشارة طبيبك المعالج.</p><p dir="RTL"><strong>قد تتفاعل الأدوية التالية مع فانكومايسين إذا تناولتها في الوقت نفسه،على سبيل المثال الأدوية التي تستخدم لعلاج: </strong></p><p dir="RTL">● العدوى التي تسببها البكتيريا (على سبيل المثال ستربتوميسين، نيومايسين، جنتاميسين، كاناميسين، أميكاسين، باسيتراسين، توبراميسين، بوليميكسين ب، كوليستين)</p><p dir="RTL">● السل (فيوميسين)</p><p dir="RTL">● العدوى الفطرية (الأمفوتريسين ب)</p><p dir="RTL">● السرطان (سيسبلاتين)</p><p dir="RTL">بالإضافة إلى</p><p dir="RTL">● الأدوية المرخية للعضلات أثناء التخدير،</p><p dir="RTL">● أدوية التخدير المخدرة (إذا كنت ستخضع للتخدير العام).</p><p dir="RTL">في حال تم إعطائك فانكومايسين بالتزامن مع أي أدوية أخرى ىسوف يقوم طبيبك المعالج بإجراء فحوصات للدم لديك وضبط الجرعة إذا لزم الأمر.</p><p dir="RTL"><strong>الحمل</strong></p><p dir="RTL">يرجى منك إخبار طبيبك المعالج قبل تلقي هذا الدواء، إذا كنت حاملاً، تعتقدين أنك حاملاً أو تخططين لذلك. يجب إعطاء فانكومايسين أثناء الحمل والرضاعة الطبيعية فقط في حالة الضرورة القصوى. سوف يقوم طبيبك المعالج بتحديد ما إذا كان يجب عليك تناول فانكومايسين أم لا.</p><p dir="RTL"><strong>الرضاعة الطبيعية</strong></p><p dir="RTL">يرجى منك إخبار طبيبك المعالج إذا كنت ترضعين طفلك رضاعة طبيعية حيث أن فانكومايسين ينتقل عبر حليب الثدي. سيقرر طبيبك ما إذا كان فانكومايسين ضرورياً أو ما إذا كان يجب عليك التوقف عن الرضاعة الطبيعية.</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">لن يؤثر فانكومايسين<strong> </strong>على قدرتك على القيادة أو استخدام الآلات أو له تأثير ضئيل جداً.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">سوف يتم إعطاء <strong>فانكولون </strong>من قبل أحد المختصين في المستشفى. سوف يقرر طبيبك المعالج مقدار الجرعة من هذا الدواء الذي يجب عليك أن تتلقاه يومياً والمدة التي سيستغرقها العلاج.</p><p dir="RTL"><strong>الجرعة </strong></p><p dir="RTL">سوف يتم تحديد مقدار الجرعة اعتماداً على:</p><p dir="RTL">&middot;&nbsp; العمر</p><p dir="RTL">&middot;&nbsp; الوزن</p><p dir="RTL">&middot;&nbsp; نوع العدوى</p><p dir="RTL">&middot;&nbsp; كفاءة عمل الكلى</p><p dir="RTL">&middot;&nbsp; قدرة السمع</p><p dir="RTL"><strong>&middot;&nbsp; </strong>أية أدوية أخرى التي من الممكن استعمالها</p><p dir="RTL"><strong><u>البالغون والمراهقون (بعمر 12 سنة فما فوق)</u></strong></p><p dir="RTL">سوف يتم تحديد مقدار الجرعة اعتماداً على وزن الجسم. يتراوح مقدار الجرعة الاعتيادية من 15 إلى 20 ملغم لكل كيلوغرام من وزن الجسم. عادة يتم إعطاء الجرعة كل 8 إلى 12 ساعة.</p><p dir="RTL">في بعض الحالات، قد يقرر طبيبك المعالج إعطائك جرعة ابتدائية يصل مقدارها إلى 30 ملغم لكل كيلوغرام من وزن الجسم. يجب عدم تجاوز مقدار الجرعة اليومية القصوى عن 2 غرام.</p><p dir="RTL"><strong><u>الاستعمال من قبل الأطفال</u></strong></p><p dir="RTL"><u>الأطفال بعمر يتراوح من شهر واحد إلى أقل من 12 سنة</u></p><p dir="RTL">سوف يتم تحديد مقدار الجرعة اعتماداً على وزن الجسم. يتراوح مقدار الجرعة الاعتيادية من 10 إلى 15 ملغم لكل كيلوغرام من وزن الجسم. عادة يتم إعطاء الجرعة كل 6 ساعات.</p><p dir="RTL"><u>الأطفال الخدج والأطفال حديثي الولادة (من بداية الولادة إلى 27 يوماً)</u></p><p dir="RTL">سوف يتم تحديد مقدار الجرعة اعتماداً على عمر ما بعد فترة الحيض (الوقت المنقضي بين اليوم الأول لآخر فترة الحيض والولادة (العمر الحملي) بالإضافة إلى الوقت المنقضي بعد الولادة (عمر ما بعد الولادة).</p><p dir="RTL">قد تحتاج الفئات التالية إلى مقدار مختلف من الجرعة: فئة كبار السن، المرأة الحامل والمرضى الذين يعانون من اضطرابات في الكلى بما في ذلك المرضى الذين يخضعون للديلزة الدموية.</p><p dir="RTL"><strong>طريقة الإعطاء </strong></p><p dir="RTL">التسريب الوريدي يعني أن الدواء يتدفق من زجاجة أو كيس التسريب عبر أنبوب إلى إحدى الأوعية الدموية وإلى الجسم.&nbsp; سوف يقوم طبيبك المعالج أو الممرض بإعطائك فانكومايسين دائمًا في الدم وليس في العضلات. سوف يتم إعطاء فانكومايسين في الوريد لمدة 60 دقيقة على الأقل.</p><p dir="RTL"><strong>مدة العلاج </strong></p><p dir="RTL">تعتمد مدة العلاج على نوع العدوى وقد يستغرق العلاج عدة أسابيع.</p><p dir="RTL">قد تختلف مدة العلاج اعتماداً على مدى استجابة كل مريض للعلاج.</p><p dir="RTL">أثناء فترة العلاج، قد تكون بحاجة إلى إجراء فحوصات الدم، إعطاء عينة من البول ومن المحتمل إجراء فحوصات للسمع للبحث عن علامات التأثيرات الجانبية المحتمل حدوثها.</p><p dir="RTL"><strong>إذا كنت تعتقد أنه تم إعطائك فانكولون بجرعة أكبر مما يجب</strong></p><p dir="RTL">نظراً أنه سوف يتم إعطائك <strong>فانكولون </strong>أثناء فترة تواجدك في المستشفى، فليس من المحتمل أن يتم إعطائك كمية كبيرة جداً. على الرغم من ذلك، يرجى منك إخبار طبيبك المعالج أو الممرض على الفور، إذا كان لديك أية استفسار.</p><p dir="RTL"><strong>يرجى منك استشارة طبيبك المعالج، الصيدلي الذي تتعامل معه أو الممرض، إذا كان لديك أية أسئلة إضافية حول استعمال هذا الدواء.</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كما هو عليه الحال مع جميع الأدوية، قد يسبب هذا الدواء تأثيرات جانبية، بالرغم من أنها قد لا تحدث لكل شخص.</p><p dir="RTL"><strong>قد يسبب فانكولون في حدوث التفاعلات التحسسية، على الرغم أن التفاعلات التحسسية خطيرة (صدمة الحساسية) ولكنها تحدث بصورة نادرة. يرجى منك إخبار طبيبك المعالج على الفور، إذا عانيت من أزيز مفاجئ، صعوبة في التنفس، احمرار الجزء العلوي من الجسم، طفح جلدي أو حكة.</strong></p><p dir="RTL">يعد معدل امتصاص فانكومايسين من الجهاز الهضمي ضئيل جداً. على الرغم من ذلك، إذا كنت تعاني من اضطراب التهابي في الجهاز الهضمي، وبصفة خاصة إذا كنت تعاني أيضاً من اضطراب في الكلى، فقد تظهر التأثيرات الجانبية الناجمة عن تلقي العلاج باستخدام فانكومايسين عن طريق التسريب الوريدي.</p><p dir="RTL"><strong>التأثيرات الجانبية الشائعة (قد تؤثر على ما يصل إلى شخص واحد من كل 10 أشخاص): </strong></p><p dir="RTL">&middot;&nbsp; انخفاض ضغط الدم</p><p dir="RTL">&middot;&nbsp; ضيق في التنفس، صوت مزعج أثناء التنفس (صوت عالي النبرة الناجم عن انسداد مجرى الهواء في الجزء العلوي من الجهاز التنفسي)</p><p dir="RTL">&middot;&nbsp; طفح جلدي والتهاب الغشاء المخاطي للفم، حكة، طفح جلدي مصحوباً بحكة، طفح جلدي على شكل خلايا النحل</p><p dir="RTL">&middot;&nbsp; اضطرابات في الكلى التي قد يتم الكشف عنها عن طريق فحوصات الدم بصورة أولية</p><p dir="RTL">&middot;&nbsp; احمرار الجزء العلوي من الجسم والوجه، التهاب الأوعية الدموية</p><p dir="RTL"><strong>التأثيرات الجانبية الغير شائعة (قد تؤثر على ما يصل إلى شخص واحد من كل 100 شخص): </strong></p><p dir="RTL">&middot;&nbsp; فقدان السمع بصورة مؤقتة أو دائمة</p><p dir="RTL"><strong>التأثيرات الجانبية النادرة (قد تؤثر على ما يصل إلى شخص واحد من كل 1000 شخص): </strong></p><p dir="RTL">&middot;&nbsp; انخفاض خلايا الدم البيضاء، خلايا الدم الحمراء، الصفائح الدموية (خلايا الدم المسؤولة على تخثر الدم)</p><p dir="RTL">&middot;&nbsp; ارتفاع بعض من أنواع خلايا الدم البيضاء في الدم</p><p dir="RTL">&middot;&nbsp; فقدان التوازن، طنين في الأذنين، دوخة</p><p dir="RTL">&middot;&nbsp; التهاب الأوعية الدموية</p><p dir="RTL">&middot;&nbsp; غثيان (الشعور بالإعياء)</p><p dir="RTL">&middot;&nbsp; التهاب الكلى، فشل كلوي</p><p dir="RTL">&middot;&nbsp; ألم في الصدر وعضلات الظهر</p><p dir="RTL">&middot;&nbsp; حمى، قشعريرة</p><p dir="RTL"><strong>التأثيرات الجانبية النادرة جداً (قد تؤثر على ما يصل إلى شخص واحد من كل 10000 شخص): </strong></p><p dir="RTL">&middot;&nbsp; حدوث تفاعلات تحسسية جلدية شديدة مصحوبة بتقرحات جلدية أو تقشر الجلد بصورة مفاجئة. قد يكون ذلك مصحوباً بحدوث حمى شديدة أو ألم في المفاصل.</p><p dir="RTL">&middot;&nbsp; سكتة قلبية</p><p dir="RTL">&middot;&nbsp; التهاب الأمعاء الذي قد يسبب ألم في البطن أو إسهال الذي قد يحتوي على الدم</p><p dir="RTL"><strong>التأثيرات الجانبية الغير معروفة (لا يمكن تقدير معدل تكرار حدوثها من البيانات المتاحة): </strong></p><p dir="RTL">&middot;&nbsp; توعك (تقيؤ)، إسهال</p><p dir="RTL">&middot;&nbsp; ارتباك، الشعور بالنعاس، خمول، تورم، احتباس السوائل، انخفاض إدرار البول</p><p dir="RTL">&middot;&nbsp; طفح جلدي مصحوباً بتورم أو ألم خلف الأذنين، الرقبة، الفخذ، أسفل الذقن والإبطين ( تورم الغدد الليمفاوية)، فحوصات غير طبيعية للدم والكبد.</p><p dir="RTL">&middot;&nbsp; طفح جلدي مصحوباً بتقرحات وحمى</p><p dir="RTL"><strong><u>للإبلاغ عن حدوث أية تأثيرات جانبية:</u></strong></p><p dir="RTL">يرجى منك إخبار طبيبك المعالج، الصيدلي في المستشفى أو الممرض، في حال حدوث أياً من التأثيرات الجانبية، بما في ذلك أية تأثيرات جانبية يحتمل حدوثها ولم يتم ذكرها في هذه النشرة. كما يمكنك الإبلاغ عن التأثيرات الجانبية مباشرة عن طريق:</p><p dir="RTL"><strong>&bull; المملكة&nbsp;العربية السعودية:</strong></p><p dir="RTL"><strong>المركز الوطني للتيقظ الدوائي:</strong></p><p dir="RTL"><strong>- مركز الاتصال الموحد: </strong>۱۹۹۹۹</p><p dir="RTL"><strong>- البريد الإلكتروني: </strong>npc.drug@sfda.gov.sa</p><p dir="RTL"><strong>- الموقع الإلكتروني:</strong> https://ade.sfda.gov.sa</p><p dir="RTL"><strong>&bull; دول الخليج العربي الأخرى:</strong></p><p dir="RTL"><strong>-</strong> الرجاء الاتصال بالجھات الوطنیة في كل دولة.</p><p dir="RTL">إن تسجيل التأثيرات الجانبية يساعد في توفير مزيد من المعلومات حول سلامة هذا الدواء.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&ndash; يحفظ بعيداً عن متناول و مرأى الأطفال.</p><p dir="RTL">&ndash; يجب عدم استعمال <strong>فانكولون</strong> بعد تاريخ انتهاء الصلاحية المذكور على العبوة والزجاجة. يشير تاريخ انتهاء الصلاحية إلى آخر يوم من الشهر المذكور.&nbsp;</p><p dir="RTL">&ndash; يحفظ&nbsp;في درجة حرارة أقل من 30&deg;م، بعيداً عن الضوء والحرارة. بعد التحضير، يتم حفظه في درجة حرارة الغرفة لمدة لا تزيد عن 42 ساعة، أو في الثلاجة (2- 8&deg;م) لمدة لا تزيد عن 96 ساعة. للمزيد من المعلومات يرجى الرجوع إلى قسم &laquo; احتياطات خاصة حول كيفية التخلص من الدواء والتداولات الأخرى&raquo;</p><p dir="RTL">&ndash; يجب عدم استعمال <strong>فانكولون</strong> إذا لاحظت وجود علامات تلف واضحة.</p><p dir="RTL">&ndash; يجب عدم التخلص من الأدوية عبر المياه المبتذلة (مياه الصرف الصحي) أو النفايات المنزلية. اسأل الصيدلي الذي تتعامل معه عن كيفية التخلص من الأدوية التي لم تعد بحاجة إليها. ستساعد هذه الإجراءات على حماية البيئة.&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفعالة هي فانكومايسين. تحتوي كل زجاجة على فانكومايسين هيدروكلوريد بما يعادل 0.5غرام أو 1 غرام من فانكومايسين.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يتوفرمسحوق <strong>فانكولون </strong>0.5 غرام المعقم للتسريب الوريدي <strong>&nbsp;</strong>في عبوات تحتوي على زجاجة واحدة أو 10 زجاجات.</p><p dir="RTL">يتوفرمسحوق <strong>فانكولون </strong>1غرام المعقم للتسريب الوريدي <strong>&nbsp;</strong>في عبوات تحتوي على زجاجة واحدة.</p><p dir="RTL">*قد لا يتم تسويق جميع العبوات الدوائية.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>الخليج للصناعات الدوائية &quot;جلفار&quot;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
             30/12/2024م
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Vancolon 1g Sterile Powder for Solution for I.V Infusion
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each vial contains:
Item No.	Material Name	Scale (mg/Vial)
		
	Active Ingredient:	
1.		Vancomycin Hydrochloride 1	1080.00
	Equivalent to Vancomycin	1000.00
		
	Inactive Ingredients:	
1.		Water for Injection, USP 2	q.s. 
2.		Nitrogen Gas 3	q.s.

1.	Assuming 925mcg Vancomycin per mg of Vancomycin hydrochloride 
2.	Does not appear in the finished product
3.	Used as air displacement agent

For a full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Sterile Powder for Solution for I.V Infusion
Description: Off-white to buff coloured lyophilized sterile powder.  
  

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Intravenous administration</u></strong></p><p>Vancomycin is indicated in all age groups for the treatment of the following infections (see sections 4.2, 4.4 and 5.1):</p><p>&sect; complicated skin and soft tissue infections (cSSTI)</p><p>&sect; bone and joint infections</p><p>&sect; community acquired pneumonia (CAP)</p><p>&sect; hospital acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP)</p><p>&sect; infective endocarditis</p><p>&sect; bacteraemia that occurs in association with, or is suspected to be associated with any of the above.</p><p>Vancomycin is also indicated in all age groups for the perioperative antibacterial prophylaxis in patients that are at high risk of developing bacterial endocarditis when undergoing major surgical procedures.</p><p>Consideration should be given to official guidance on the appropriate use of antibacterial agents.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Posology</u></strong></p><p>Where appropriate, vancomycin should be administered in combination with other antibacterial agents.</p><p><strong>Intravenous administration</strong></p><p>The initial dose should be based on total body weight. Subsequent dose adjustments should be based on serum concentrations to achieve targeted therapeutic concentrations.</p><p>Renal function must be taken into consideration for subsequent doses and interval of administration.</p><p><strong><u>Patients aged 12 years and older</u></strong></p><p>The recommended dose is 15 to 20 mg/kg of body weight every 8 to 12 h (not to exceed 2 g per dose).</p><p>In seriously ill patients, a loading dose of 25&ndash;30 mg/kg of body weight can be used to facilitate rapid attainment of target trough serum vancomycin concentration.</p><p><strong><u>Infants and children aged from one month to less than 12 years of age:</u></strong></p><p>The recommended dose is 10 to 15 mg/kg body weight every 6 hours (see section 4.4).</p><p><strong><u>Term neonates (from birth to 27 days of post-natal age) and preterm neonates (from birth to the expected date of delivery plus 27 days)</u></strong></p><p>For establishing the dosing regimen for neonates, the advice of a physician experienced in the management of neonates should be sought. One possible way of dosing vancomycin in neonates is illustrated in the following table: (see section 4.4)</p><table border="1" cellspacing="0" cellpadding="0" style="width:542px"><tbody><tr><td style="vertical-align:top"><p><strong>PMA (weeks)</strong></p></td><td style="vertical-align:top"><p><strong>Dose (mg/kg)</strong></p></td><td style="vertical-align:top"><p><strong>Interval of administration (h)</strong></p></td></tr><tr><td style="vertical-align:top"><p>&lt;29</p></td><td style="vertical-align:top"><p>15</p></td><td style="vertical-align:top"><p>24</p></td></tr><tr><td style="vertical-align:top"><p>29-35</p></td><td style="vertical-align:top"><p>15</p></td><td style="vertical-align:top"><p>12</p></td></tr><tr><td style="vertical-align:top"><p>&gt;35</p></td><td style="vertical-align:top"><p>15</p></td><td style="vertical-align:top"><p>8</p></td></tr></tbody></table><p>PMA: post-menstrual age [(time elapsed between the first day of the last menstrual period and birth (gestational age) plus the time elapsed after birth (post-natal age)].</p><p><strong><u>Peri-operative prophylaxis of bacterial endocarditis in all age groups</u></strong></p><p>The recommended dose is an initial dose of 15 mg/kg prior to induction of anaesthesia. Depending on the duration of surgery, a second vancomycin dose may be required.</p><p><strong>Duration of treatment</strong></p><p>Suggested treatment duration is shown in table below. In any case, the duration of treatment should be tailored to the type and severity of infection and the individual clinical response.</p><table border="1" cellspacing="0" cellpadding="0" style="width:540px"><tbody><tr><td style="vertical-align:top"><p><strong>Indication</strong></p></td><td style="vertical-align:top"><p><strong>Treatment duration</strong></p></td></tr><tr><td style="vertical-align:top"><p>Complicated skin and soft tissue infections</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>- Non necrotizing</p></td><td style="vertical-align:top"><p>7 to 14 days</p></td></tr><tr><td style="vertical-align:top"><p>- Necrotizing</p></td><td style="vertical-align:top"><p>4 to 6 weeks*</p></td></tr><tr><td style="vertical-align:top"><p>Bone and joint infections</p></td><td style="vertical-align:top"><p>4 to 6 weeks**</p></td></tr><tr><td style="vertical-align:top"><p>Community-acquired pneumonia</p></td><td style="vertical-align:top"><p>7 to 14 days</p></td></tr><tr><td style="vertical-align:top"><p>Hospital-acquired pneumonia, including ventilator-associated pneumonia</p></td><td style="vertical-align:top"><p>7 to 14 days</p></td></tr><tr><td style="vertical-align:top"><p>Infective endocarditis</p></td><td style="vertical-align:top"><p>4 to 6 weeks***</p></td></tr></tbody></table><p>*Continue until further debridement is not necessary, patient has clinically improved, and patient is afebrile for 48 to 72 hours</p><p>**Longer courses of oral suppression treatment with suitable antibiotics should be considered for prosthetic joint infections</p><p>***Duration and need for combination therapy is based on valve-type and organism</p><p><strong><u>Special populations</u></strong></p><p><strong>Elderly</strong></p><p>Lower maintenance doses may be required due to the age-related reduction in renal function.</p><p><strong>Renal impairment</strong></p><p>In adult and paediatric patients with renal impairment, consideration should be given to an initial starting dose followed by serum vancomycin trough levels rather than to a scheduled dosing regimen, particularly in patients with severe renal impairment or those who undergo renal replacement therapy (RRT) due to the many varying factors that may affect vancomycin levels in them. In patients with mild or moderate renal failure, the starting dose must not be reduced. In patients with severe renal failure, it is preferable to prolong the interval of administration rather than administer lower daily doses.</p><p>Appropriate consideration should be given to the concomitant administration of medicinal products that may reduce vancomycin clearance and/or potentiate its undesirable effects (see section 4.4).</p><p>Vancomycin is poorly dialyzable by intermittent haemodialysis. However, use of high-flux membranes and continuous renal replacement therapy (CRRT) increases vancomycin clearance and generally requires replacement dosing (usually after the haemodialysis session in case of intermittent haemodialysis).</p><p><strong>Adults</strong></p><p>Dose adjustments in adult patients could be based on glomerular filtration rate estimated (eGFR) by the following formula:</p><p>Men: [Weight (kg) x 140 - age (years)]/ 72 x serum creatinine (mg/dl)</p><p>Women: 0.85 x value calculated by the above formula.</p><p>The usual starting dose for adult patients is 15 to 20 mg/kg that could be administered every 24 hours in patients with creatinine clearance between 20 to 49 ml/min. In patients with severe renal impairment (creatinine clearance below 20 ml/min) or those on renal replacement therapy, the appropriate timing and amount of subsequent doses largely depend on the modality of RRT and should be based on serum vancomycin trough levels and on residual renal function (see section 4.4). Depending on the clinical situation, consideration could be given to withhold the next dose while awaiting the results of vancomycin levels.</p><p>In the critically ill patient with renal insufficiency, the initial loading dose (25 to 30 mg/kg) should not be reduced.</p><p><strong>Paediatric population</strong></p><p>Dose adjustments in paediatric patients aged 1 year and older could be based on glomerular filtration rate estimated (eGFR) by the revised Schwartz formula:</p><p>eGFR (mL/min/1.73m<sup>2&nbsp;</sup>) = (height cm x 0.413)/ serum creatinine (mg/dl)</p><p>eGFR (mL/min/1.73m<sup>2</sup>)= (height cm x 36.2/serum creatinine (&mu;mol/L)</p><p>For neonates and infants below 1 year of age, expert advice should be sought as the revised Schwartz formula is not applicable to them.</p><p>Orientative dosing recommendations for the paediatric population are shown in table below that follow the same principles as in adult patients.</p><table border="1" cellspacing="0" cellpadding="0" style="width:539px"><tbody><tr><td style="vertical-align:top"><p><strong>GFR (mL/min/1.73 m<sup>2</sup>)</strong></p></td><td style="vertical-align:top"><p><strong>IV dose</strong></p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p></td></tr><tr><td style="vertical-align:top"><p>50-30</p></td><td style="vertical-align:top"><p>15 mg/kg</p></td><td style="vertical-align:top"><p>12 hourly</p></td></tr><tr><td style="vertical-align:top"><p>29-10</p></td><td style="vertical-align:top"><p>15 mg/kg</p></td><td style="vertical-align:top"><p>24 hourly</p></td></tr><tr><td style="vertical-align:top"><p>&lt; 10</p></td><td rowspan="3" style="vertical-align:top"><p>10-15 mg/kg</p></td><td rowspan="3" style="vertical-align:top"><p>Re-dose based on levels*</p></td></tr><tr><td style="vertical-align:top"><p>Intermittent haemodialysis</p></td></tr><tr><td style="vertical-align:top"><p>Peritoneal dialysis</p></td></tr><tr><td style="vertical-align:top"><p>Continuous renal replacement therapy</p></td><td style="vertical-align:top"><p>15 mg/kg</p></td><td style="vertical-align:top"><p>Re-dose based on levels*</p></td></tr></tbody></table><p>*The appropriate timing and amount of subsequent doses largely depends on the modality of RRT and should be based on serum vancomycin levels obtained prior to dosing and on residual renal function. Depending on the clinical situation, consideration could be given to withhold the next dose while awaiting the results of vancomycin levels.</p><p><strong>Hepatic impairment:</strong></p><p>No dose adjustment is needed in patients with hepatic insufficiency.</p><p><strong>Pregnancy</strong></p><p>Significantly increased doses may be required to achieve therapeutic serum concentrations in pregnant women (see Section 4.6).</p><p><strong>Obese patients</strong></p><p>In obese patients, the initial dose should be individually adapted according to total body weight as in non-obese patients.</p><p><strong><u>Method of administration</u></strong></p><p><strong>Intravenous administration</strong></p><p>Intravenous vancomycin is usually administered as an intermittent infusion and the dosing recommendations presented in this section for the intravenous route correspond to this type of administration.</p><p>Vancomycin shall only be administered as slow intravenous infusion of at least one hour duration or at a maximum rate of 10 mg/min (whichever is longer) which is sufficiently diluted (at least 100 ml per 500 mg or at least 200 ml per 1000 mg) (see section 4.4).</p><p>Patients whose fluid intake must be limited can also receive a solution of 500 mg/50 ml or 1000 mg/100 ml, although the risk of infusion-related undesirable effects can be increased with these higher concentrations.</p><p>For information about the preparation of the solution, please see section 6.6<em>.</em></p><p>Continuous vancomycin infusion may be considered, e.g., in patients with unstable vancomycin clearance.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                	Hypersensitivity to the active substance.
	Vancomycin should not be administered intramuscularly due to the risk of necrosis at the site of administration.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Hypersensitivity reactions</u></strong></p><p>Serious and occasionally fatal hypersensitivity reactions are possible (see sections 4.3 and 4.8). In case of hypersensitivity reactions, treatment with vancomycin must be discontinued immediately and the adequate emergency measures must be initiated.</p><p>In patients receiving vancomycin over a longer-term period or concurrently with other medications which may cause neutropenia or agranulocytosis, the leukocyte count should be monitored at regular intervals. All patients receiving vancomycin should have periodic haematologic studies, urine analysis, liver and renal function tests.</p><p>Vancomycin should be used with caution in patients with allergic reactions to teicoplanin, since cross hypersensitivity, including fatal anaphylactic shock, may occur.</p><p><strong><u>Spectrum of antibacterial activity</u></strong></p><p>Vancomycin has a spectrum of antibacterial activity limited to Gram-positive organisms. It is not suitable for use as a single agent for the treatment of some types of infections unless the pathogen is already documented and known to be susceptible or there is a high suspicion that the most likely pathogen(s) would be suitable for treatment with vancomycin.</p><p>The rational use of vancomycin should take into account the bacterial spectrum of activity, the safety profile and the suitability of standard antibacterial therapy to treat the individual patient.</p><p><strong><u>Ototoxicity</u></strong></p><p>Ototoxicity, which may be transitory or permanent (see section 4.8) has been reported in patients with prior deafness, who have received excessive intravenous doses, or who receive concomitant treatment with another ototoxic active substance such as an aminoglycoside. Vancomycin should also be avoided in patients with previous hearing loss. Deafness may be preceded by tinnitus. Experience with other antibiotics suggests that deafness may be progressive despite cessation of treatment. To reduce the risk of ototoxicity, blood levels should be determined periodically and periodic testing of auditory function is recommended.</p><p>The elderly are particularly susceptible to auditory damage. Monitoring of vestibular and auditory function in the elderly should be carried out during and after treatment. Concurrent or sequential use of other ototoxic substances should be avoided.</p><p><strong><u>Infusion-related reactions</u></strong></p><p>Rapid bolus administration (i.e. over several minutes) may be associated with exaggerated hypotension (including shock and, rarely, cardiac arrest), histamine like responses and maculopapular or erythematous rash (&ldquo;red man&#39;s syndrome&rdquo; or &ldquo;red neck syndrome&rdquo;). Vancomycin should be infused slowly in a dilute solution (2.5 to 5.0 mg/ml) at a rate no greater than 10 mg/min and over a period not less than 60 minutes to avoid rapid infusion-related reactions. Stopping the infusion usually results in a prompt cessation of these reactions.</p><p>The frequency of infusion-related reactions (hypotension, flushing, erythema, urticaria and pruritus) increases with the concomitant administration of anaesthetic agents (see section 4.5). This may be reduced by administering vancomycin by infusion over at least 60 minutes, before anaesthetic induction.</p><p><strong><u>Severe bullous reactions</u></strong></p><p>Stevens-Johnson syndrome (SJS) has been reported with the use of vancomycin (see section4.8). If symptoms or signs of SJS (e.g. progressive skin rash often with blisters or mucosal lesions) are present, vancomycin treatment should be discontinued immediately and specialised dermatological assessment be sought.</p><p><strong><u>Administration site related reactions</u></strong></p><p>Pain and thrombophlebitis may occur in many patients receiving intravenous vancomycin and are occasionally severe. The frequency and severity of thrombophlebitis can be minimized by administering the medicinal product slowly as a dilute solution (see section 4.2) and by changing the sites of infusion regularly.</p><p>The efficacy and safety of vancomycin has not been established for the intrathecal, intralumbar and intraventricular routes of administration.</p><p><strong><u>Nephrotoxicity</u></strong></p><p>Serial monitoring of renal function should be performed when treating patients with underlying renal dysfunction or patients receiving concomitant therapy with an aminoglycoside or other nephrotoxic drugs.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p><strong><u>Other potentially nephrotoxic or ototoxic medications</u></strong></p><p>Concurrent or sequential administration of vancomycin with other potentially neurotoxic or/and nephrotoxic active substances particularly gentamycin, amphotericin B, streptomycin, neomycin, kanamycin, amikacin, tobramycin, viomycin, bacitracin, polymyxin B, colistin and cisplatin may potentiate the nephrotoxicity and/orototoxicity of vancomycin and consequently requires careful monitoring of the patient.</p><p><strong><u>Anaesthetics</u></strong></p><p>Concurrent administration of vancomycin and anaesthetic agents has been associated with erythema, histamine like flushing and anaphylactoid reactions. This may be reduced if the vancomycin is administered over 60 minutes before anaesthetic induction.</p><p><strong><u>Muscle relaxants</u></strong></p><p>If vancomycin is administered during or directly after surgery, the effect (neuromuscular blockade) of muscle relaxants(such as succinylcholine) concurrently used can be enhanced and prolonged.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Pregnancy</u></strong></p><p>No sufficient safety experience is available regarding vancomycin during human pregnancy. Reproduction toxicological studies on animals do not suggest any effects on the development of the embryo, foetus or gestation period (see section 5.3).</p><p>However, vancomycin penetrates the placenta and a potential risk of embryonal and neonatal ototoxicity and nephrotoxicity cannot be excluded. Therefore vancomycin should be given in pregnancy only if clearly needed and after a careful risk/benefit evaluation.</p><p><strong><u>Breast-feeding</u></strong></p><p>Vancomycin is excreted in human milk and should be therefore used in lactation period only if clearly necessary. Vancomycin should be cautiously given to breast-feeding mothers because of potential adverse reactions in the infant (disturbances in the intestinal flora with diarrhoea, colonisation with yeast-like fungi and possibly sensibilisation). Considering the importance of this medicine for nursing mother, the decision to stop breastfeeding should be considered.</p><p>&nbsp;&nbsp;&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Vancomycin has no or negligible influence on the ability to drive or use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Summary of the Safety profile</u></strong></p><p>The most common adverse reactions are phlebitis, pseudo-allergic reactions and flushing of the upper body (&ldquo;red-neck syndrome&rdquo;) in connection with too rapid intravenous infusion of vancomycin.</p><p>The absorption of vancomycin from the gastrointestinal tract is negligible. However, in severe inflammation of the intestinal mucosa, especially in combination with renal insufficiency, adverse reactions that occur when vancomycin is administered parenterally may appear.</p><p><strong><u>Tabulated List of Adverse reactions</u></strong></p><p>Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.</p><p>The adverse reactions listed below are defined using the following MedDRA convention and system organ class database:</p><p>Very common (&ge; 1/10); common (&ge; 1/100 to &lt; 1/10); uncommon (&ge; 1/1,000 to &lt; 1/100); rare (&ge; 1/10,000 to &lt; 1/1,000); very rare (&lt; 1/10,000), not known (cannot be estimated from the available data).</p><table border="1" cellspacing="0" cellpadding="0" style="width:540px"><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong>System organ class</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Frequency</strong></p></td><td style="vertical-align:top"><p><strong>Adverse reaction</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Blood and the lymphatic system disorders:</strong></p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Reversible neutropenia, agranulocytosis, eosinophilia, thrombocytopenia, pancytopenia.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Immune system disorders:</strong></p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Hypersensitivity reactions, anaphylactic reactions</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Ear and labyrinth disorders:</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Transient or permanent loss of hearing</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Vertigo, tinnitus, dizziness</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Cardiac disorders:</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Cardiac arrest</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Vascular disorders:</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Decrease in blood pressure</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Vasculitis</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders:</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Dyspnoea, stridor</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Gastrointestinal disorders:</strong></p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Nausea</p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Pseudomembranous enterocolitis</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Vomiting, Diarrhoea</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders:</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Flushing of the upper body (&ldquo;red man syndrome&rdquo;), exanthema and mucosal inflammation, pruritus, urticaria</p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Exfoliative dermatitis, Stevens-Johnson syndrome, Lyell&#39;s syndrome, Linear IgA bullous dermatosis.</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Eosinophilia and systemic symptoms (DRESS syndrome), AGEP (Acute Generalized Exanthematous Pustulosis)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Renal and urinary disorders:</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Renal insufficiency manifested primarily by increased serum creatinine and serum urea</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Interstitial nephritis, acute renal failure.</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Acute tubular necrosis</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>General disorders and administration site conditions:</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Phlebitis, redness of the upper body and face.</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Drug fever, shivering, Pain and muscle spasm of the chest and back muscles</p></td></tr></tbody></table><p><strong><u>Description of selected adverse drug reactions</u></strong></p><p>Reversible neutropenia usually starting one week or more after onset of intravenous therapy or after total dose of more than 25 g.</p><p>During or shortly after rapid infusion anaphylactic/anaphylactoid reactions including wheezing may occur. The reactions abate when administration is stopped, generally between 20 minutes and 2 hours. Vancomycin should be infused slowly (see sections 4.2 and 4.4). Necrosis may occur after intramuscular injection.</p><p>Tinnitus, possibly preceding onset of deafness, should be regarded as an indication to discontinue treatment.</p><p>Ototoxicity has primarily been reported in patients given high doses, or in those on concomitant treatment with other ototoxic medicinal product like aminoglycoside, or in those who had a pre-existing reduction in kidney function or hearing. If a bullous disorder is suspected, the drug should be discontinued and specialised dermatological assessment should be carried out.</p><p><strong><u>&nbsp;</u></strong></p><p><strong><u>Paediatric population</u></strong></p><p>The safety profile is generally consistent among children and adult patients. Nephrotoxicity has been described in children, usually in association with other nephrotoxic agents such as aminoglycosides.</p><p><strong><u>&nbsp;</u></strong></p><p><strong><u>Healthcare professionals are asked to report any suspected adverse reactions via:</u></strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong><u>Saudi Arabia:</u></strong></p><p><strong>&nbsp;&nbsp;&nbsp;&nbsp; The National Pharmacovigilance Centre (NPC):</strong></p><p><strong>&nbsp; &nbsp;&nbsp; - SFDA Call Centre: </strong>19999</p><p><strong>&nbsp;&nbsp; &nbsp; - E-mail: </strong>npc.drug@sfda.gov.sa</p><p><strong>&nbsp;&nbsp; &nbsp; </strong><strong>- Website: </strong>https://ade.sfda.gov.sa</p><p>&middot; <strong><u>Other GCC States:</u></strong></p><p>&nbsp;&nbsp; &nbsp; - Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Toxicity due to overdose has been reported. 500 mg iv to a child, 2 year of age, resulted in lethal intoxication. Administration of a total of 56 g during 10 days to an adult resulted in renal insufficiency. In certain high-risk conditions(e. g. in case of severe renal impairment) high serum levels and oto- and nephrotoxic effects can occur.</p><p>Measures in case of overdose:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A specific antidote is not known.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Symptomatic treatment while maintaining renal function is required</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vancomycin is poorly removed from the blood by haemodialysis or peritoneal dialysis. Haemofiltration or haemoperfusion with polysulfone resins have been used to reduce serum concentrations of vancomycin.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pharmacotherapeutic group: </strong>glycopeptide antibacterials</p><p><strong>ATC Code: </strong>J01 XA01 for intravenous use</p><p><strong><u>Mechanism of action</u></strong></p><p>Vancomycin is a tricyclic glycopeptide antibiotic that inhibits the synthesis of the cell wall in sensitive bacteria by binding with high affinity to the D-alanyl-D-alanine terminus of cell wall precursor units. The drug is slowly bactericidal for dividing microorganisms. In addition, it impairs the permeability of the bacterial cell membrane and RNA synthesis.</p><p><strong><u>Pharmacokinetic/ Pharmacodynamic relationship</u></strong></p><p>Vancomycin displays concentration-independent activity with the area under the concentration curve (AUC) divided by the minimum inhibitory concentration (MIC) of the target organism as the primary predictive parameter for efficacy. On basis of in vitro, animal and limited human data, an AUC/MIC ratio of 400 has been established as a PK/PD target to achieve clinical effectiveness with vancomycin. To achieve this target when MICs are &ge; 1.0 mg/l, dosing in the upper range and high trough serum concentrations &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(15-20 mg/l) are required (see section 4.2).</p><p><strong><u>Mechanism of resistance</u></strong></p><p>Acquired resistance to glycopeptides is most common in enterococci and is based on acquisition of various van gene complexes which modifies the D-alanyl-D-alanine target to D-alanyl-D-lactate or D-alanyl-D-serine which bind vancomycin poorly. In some countries, increasing cases of resistance are observed particularly in enterococci; multi-resistant strains of Enterococcus faecium are especially alarming.</p><p>Van genes have rarely been found in&nbsp;<em>Staphylococcus aureus</em>, where changes in cell wall structure result in &ldquo;intermediate&rdquo; susceptibility, which is most commonly heterogeneous. Also, methicillin-resistant&nbsp;<em>staphylococcus&nbsp;</em>strains (MRSA) with reduced susceptibility for vancomycin were reported. The reduced susceptibility or resistance to vancomycin in&nbsp;<em>Staphylococcus&nbsp;</em>is not well understood. Several genetic elements and multiple mutations are required.</p><p>There is no cross-resistance between vancomycin and other classes of antibiotics. Cross-resistance with other glycopeptide antibiotics, such as teicoplanin, does occur. Secondary development of resistance during therapy is rare.</p><p><strong><u>Synergism</u></strong></p><p>The combination of vancomycin with an aminoglycoside antibiotic has a synergistic effect against many strains of&nbsp;<em>Staphylococcus aureus</em>, non-enterococcal group D-streptococci, enterococci and streptococci of the&nbsp;<em>Viridans&nbsp;</em>group. The combination of vancomycin with a cephalosporin has a synergistic effect against some oxacillin-resistant&nbsp;<em>Staphylococcus epidermidis&nbsp;</em>strains, and the combination of vancomycin with rifampicin has a synergistic effect against&nbsp;<em>Staphylococcus epidermidis&nbsp;</em>and a partial synergistic effect against some&nbsp;<em>Staphylococcus aureus&nbsp;</em>strains. As vancomycin in combination with a cephalosporin may also have an antagonistic effect against some&nbsp;<em>Staphylococcus epidermidis&nbsp;</em>strains and in combination with rifampicin against some&nbsp;<em>Staphylococcus aureus&nbsp;</em>strains, preceding synergism testing is useful.</p><p>Specimens for bacterial cultures should be obtained in order to isolate and identify the causative organisms and to determine their susceptibility to vancomycin.</p><p><strong><u>Susceptibility testing breakpoints</u></strong></p><p>Vancomycin is active against gram-positive bacteria, such as staphylococci, streptococci, enterococci, pneumococci, and clostridia. Gram-negative bacteria are resistant.</p><p>The prevalence of acquired resistance may vary geographically and with time for selected species and local information on resistance is desirable, particularly when treating severe infections. As necessary, expert advice should be sought when the local prevalence of resistance is such that the utility of the agent in at least some types of infections is questionable. This information only provides approximate guidance on the chance whether micro-organisms are susceptible to vancomycin.</p><p>Minimum inhibitory concentration (MIC) breakpoints established by the European Committee on Antimicrobial Susceptibility Testing (EUCAST) are as follows:</p><table border="1" cellspacing="0" cellpadding="0" style="width:540px"><tbody><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Susceptible</p></td><td style="vertical-align:top"><p>Resistant</p></td></tr><tr><td style="vertical-align:top"><p><em>Staphylococcus aureus<sup>1</sup></em></p></td><td style="vertical-align:top"><p>&le; 2 mg/L</p></td><td style="vertical-align:top"><p>&gt; 2 mg/L</p></td></tr><tr><td style="vertical-align:top"><p>Coagulase-negative staphylococci<sup>1</sup></p></td><td style="vertical-align:top"><p>&le; 4 mg/L</p></td><td style="vertical-align:top"><p>&gt; 4 mg/L</p></td></tr><tr><td style="vertical-align:top"><p><em>Enterococcus&nbsp;</em>spp.</p></td><td style="vertical-align:top"><p>&le; 4 mg/L</p></td><td style="vertical-align:top"><p>&gt; 4 mg/L</p></td></tr><tr><td style="vertical-align:top"><p>Streptococcus groups A, B, C and G</p></td><td style="vertical-align:top"><p>&le; 2 mg/L</p></td><td style="vertical-align:top"><p>&gt; 2 mg/L</p></td></tr><tr><td style="vertical-align:top"><p><em>Streptococcus pneumoniae</em></p></td><td style="vertical-align:top"><p>&le; 2 mg/L</p></td><td style="vertical-align:top"><p>&gt; 2 mg/L</p></td></tr><tr><td style="vertical-align:top"><p>Gram positive anaerobes</p></td><td style="vertical-align:top"><p>&le; 2 mg/L</p></td><td style="vertical-align:top"><p>&gt; 2 mg/L</p></td></tr></tbody></table><p><sup>1</sup><em>S. aureus</em>&nbsp;with vancomycin MIC values of 2 mg/L are on the border of the wild type distribution and there may be an impaired clinical response.</p><table border="1" cellspacing="0" cellpadding="0" style="width:542px"><tbody><tr><td style="vertical-align:top"><p><strong><u>Commonly susceptible species</u></strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Gram positive</strong></p><p><em>Enterococcus faecalis</em></p><p><em>Staphylococcus aureus</em></p><p>Methicillin-resistant&nbsp;<em>Staphylococcus aureus</em></p><p>coagulase-negative Staphylococci</p><p><em>Streptococcus&nbsp;</em>spp<em>.</em></p><p><em>Streptococcus pneumoniae</em></p><p><em>Enteroccocus&nbsp;</em>spp<em>.</em></p><p><em>Staphylococcus&nbsp;</em>spp<em>.</em></p><p><strong>Anaerobic species</strong></p><p><em>Clostridium&nbsp;</em>spp<em>. except Clostridium innocuum</em></p><p><em>Eubacterium&nbsp;</em>spp<em>.</em></p><p><em>Peptostreptococcus&nbsp;</em>spp<em>.</em></p></td></tr><tr><td style="vertical-align:top"><p><strong><u>Species for which acquired resistance may be a problem</u></strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Enterococcus faecium</em></p></td></tr><tr><td style="vertical-align:top"><p><strong><u>Inherently resistant</u></strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>All Gram negative bacteria</strong></p><p><strong>Gram positive aerobic species</strong></p><p><em>Erysipelothrix rhusiopathiae,</em></p><p><em>Heterofermentative Lactobacillus,</em></p><p><em>Leuconostoc&nbsp;</em>spp</p><p><em>Pediococcus&nbsp;</em>spp<em>.</em></p><p><strong>Anaerobic species</strong></p><p><em>Clostridium innocuum</em></p></td></tr><tr><td style="vertical-align:top"><p>The emergence of resistance towards vancomycin differs from one hospital to another and a local microbiological laboratory should therefore be contacted for relevant local information.</p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Absorption</u></strong></p><p>Vancomycin is administered intravenously for the treatment of systemic infections.</p><p>In the case of patients with normal renal function, intravenous infusion of multiple doses of 1g vancomycin (15 mg/kg) for 60 minutes produces approximate average plasma concentrations of 50-60 mg/L, 20-25 mg/L and 5-10 mg/L, immediately, 2 hours and 11 hours after completing the infusion, respectively. The plasma levels obtained after multiple doses are similar to those achieved after a single dose.</p><p><strong><u>Distribution</u></strong></p><p>The volume of distribution is about 60 L/1.73 m<sup>2&nbsp;</sup>body surface. At serum concentrations of vancomycin of 10 mg/l to 100 mg/l, the binding of the drug to plasma proteins is approximately 30-55%, measured by ultra-filtration.</p><p>Vancomycin diffuses readily across the placenta and is distributed into cord blood. In non-inflamed meninges, vancomycin passes the blood-brain barrier only to a low extent.</p><p><strong><u>Biotransformation</u></strong></p><p>There is very little metabolism of the drug. After parenteral administration it is excreted almost completely as microbiologically active substance (approx. 75-90% within 24 hours) through glomerular filtration via the kidneys.</p><p><strong><u>Elimination</u></strong></p><p>The elimination half-life of vancomycin is 4 to 6 hours in patients with normal renal function and 2.2-3 hours in children. Plasma clearance is about 0.058 L/kg/h and kidney clearance about 0.048 L/kg/h. In the first 24 hours, approximately 80 % of an administered dose of vancomycin is excreted in the urine through glomerular filtration. Renal dysfunction delays the excretion of vancomycin. In anephric patients, the mean half-life is 7.5 days. Due to ototoxicity of vancomycin therapy-adjuvant monitoring of the plasma concentrations is indicated in such cases.</p><p>Biliary excretion is insignificant (less than 5% of a dose).</p><p>Although the vancomycin is not eliminated efficiently by haemodialysis or peritoneal dialysis, there have been reports of an increase in vancomycin clearance with haemoperfusion and haemofiltration.</p><p><strong><u>Linerarity/non-linearity</u></strong></p><p>Vancomycin concentration generally increases proportionally with increasing dose. Plasma concentrations during multiple dose administration are similar to those after the administration of a single dose.</p><p><strong><u>Characteristics in specific groups</u></strong></p><p><strong>Renal impairment</strong></p><p>Vancomycin is primarily cleared by glomerular filtration. In patients with impaired renal function the terminal elimination half- life of vancomycin is prolonged and the total body clearance is reduced. Subsequently, optimal dose should be calculated in line with dosing recommendations provided in section 4.2. Posology and method of administration.</p><p><strong>Hepatic impairment</strong></p><p>Vancomycin pharmacokinetics is not altered in patients with hepatic impairment.</p><p><strong>Pregnant Women:</strong></p><p>Significantly increased doses may be required to achieve therapeutic serum concentrations in pregnant women (see Section 4.6).</p><p><strong>Overweight patients</strong></p><p>Vancomycin distribution may be altered in overweight patients due to increases in volume of distribution, in renal clearance and possible changes in plasma protein binding. In these subpopulations vancomycin serum concentration were found higher than expected in male healthy adults (see section 4.2).</p><p><strong><u>Paediatric population</u></strong></p><p>Vancomycin PK has shown wide inter-individual variability in preterm and term neonates. In neonates, after intravenous administration, vancomycin volume of distribution varies between 0.38 and 0.97 L/kg, similar to adult values, while clearance varies between 0.63 and 1.4 ml/kg/min. Half-life varies between 3.5 and 10 h and is longer than in adults, reflecting the usual lower values for clearance in the neonate.</p><p>In infants and older children, the volume of distribution ranges between 0.26-1.05 L/kg while clearance varies between 0.33-1.87 ml/kg/min.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Although no long-term studies in animals have been performed to evaluate carcinogenic potential, no mutagenic potential of vancomycin was found in standard laboratory tests. No definitive fertility studies have been performed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="0" cellspacing="0" cellpadding="0" style="width:0px"><tbody><tr><td style="vertical-align:top"><p><strong><u>Inactive Ingredients:</u></strong></p></td></tr><tr><td style="vertical-align:top"><ol><li>Water for Injection, USP <sup>1</sup></li></ol></td></tr><tr><td style="vertical-align:top"><ol><li>Nitrogen Gas <sup>2</sup></li></ol><p>&nbsp;</p></td></tr></tbody></table><p><sup>1.</sup> Does not appear in the finished product</p><p><sup>2.</sup> Used as air displacement agent</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Vancomycin solution has a low pH that may cause chemical or physical instability when it is mixed with other compounds.</p><p>Mixing with alkaline solutions should be avoided. Therefore, each parental solution should be checked visually for precipitation and discolouration prior to use.</p><p>This medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Before preparation: 36 months from the date of manufacturing.
After preparation: Chemical and physical in- use stability has been demonstrated for a period of 24 hours at room temperature after preparation by using water for injection and for a period of 96 hours when stored in a refrigerator (2-8°C) after preparation by using 0.9% Sodium chloride or 5% Dextrose.
From a microbiological point of view, the product should be used immediately.
If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user, unless reconstitution and dilution has taken place in controlled and validated aseptic conditions.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30<sup>o</sup>C. Protect from light and heat.</p><p><strong><u>After preparation:&nbsp; </u></strong>For storage conditions of the prepared solution see section 6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pack of 1 Vial:</strong> USP TYPE-1 flint glass vial, sealed with rubber stopper and white flip-off aluminium-plastic cap, one vial packed in a printed carton along with a leaflet.</p><p><strong>Pack of 10 Vials:</strong> USP TYPE-1 flint glass vial, sealed with rubber stopper and white flip-off aluminium-plastic cap, 10 vials packed in a printed carton along with a leaflet.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Reconstituted solutions containing 50 mg/ml of vancomycin should be further diluted depending on the method of administration.</p><p><strong><u>Preparation of the reconstituted solution</u></strong></p><p>Dissolve the powder in 20 ml of sterile Water for injection</p><p>One ml of reconstituted solution contains 50 mg of vancomycin.</p><p><strong><u>Appearance of reconstituted solution</u></strong></p><p>After reconstitution, the solution is clear and colourless or light to dark tan solution.</p><p>For storage conditions of the prepared solution, see section 6.3.</p><p><strong><u>Preparation of final diluted Solution for infusion</u></strong></p><p>Reconstituted solutions containing 50 mg/ml of vancomycin should be further diluted.</p><p>Suitable diluents are:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0.9% Sodium chloride</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 5% Dextrose<strong><em> </em></strong></p><p><strong><em>Intermittent infusion:</em></strong></p><p>Reconstituted solution containing 1000 mg vancomycin (50 mg/ml) must be diluted further with at least 200 ml diluent (to 5 mg/ml)</p><p>The concentration of vancomycin in Solution for infusion should not exceed 5 mg/ml.</p><p>The desired dose should be administered slowly by intravenous use at a rate of no more than 10 mg/minute, for at least 60 minutes or even longer.</p><p><strong><em>Continuous infusion:</em></strong></p><p>This should be used only if treatment with an intermittent infusion is not possible. Dilute 1000 mg to 2000 mg of dissolved vancomycin in a sufficient amount of the above suitable diluent and administer it in the form of a drip infusion, so that the patient will receive the prescribed daily dose in 24 hours.</p><p><strong><u>Appearance of diluted solution</u></strong></p><p>After dilution, the solution is clear, free from foreign particles.</p><p>For storage conditions of the prepared solution, see section 6.3.</p><p>Before administration, the reconstituted and diluted solutions should be inspected visually for particulate matter and discoloration. Only clear, and colorless solution free from particles should be used.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Gulf Pharmaceutical Industries - Julphar
Digdaga, Airport Street
Ras Al Khaimah - United Arab Emirates
P.O. Box 997
Tel. No.: (9717) 2 461 461
Fax No.: (9717) 2 462 462

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                30. December. 2024
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>